This segment focuses on providing comprehensive preclinical research services for a wide range of infectious diseases, including COVID-19, AIDS, influenza, and other viral infections like Zika and Dengue. Research and Development activities include in-vivo and in-vitro studies using various animal models, virus stock generation, and the development of assays to measure viral load and neutralization. Technologies and methodologies employed encompass quantitative PCR, ELISA detection assays, flow cytometry, and lymphocyte proliferation assays. The segment's therapeutic areas cover a broad spectrum of viral and parasitic infections, aiming to improve patient outcomes through the development of effective vaccines and antiviral therapies. BIOQUAL's market positioning is strong due to its expertise in animal models and its collaborations with government agencies and private companies. Future opportunities include expanding research into emerging infectious diseases and developing novel therapeutic approaches. Regulatory and clinical aspects are addressed through adherence to AAALAC accreditation and compliance with relevant guidelines. Partnerships with organizations like the NIH and private companies are crucial for advancing research and development efforts.

This segment is dedicated to providing preclinical research services focused on cancer, including in-vivo and in-vitro studies. Research and Development activities involve the use of animal models to evaluate the efficacy and safety of novel cancer therapies. Technologies and methodologies include cell-based assays, flow cytometry, and the development of assays to detect and quantify cancer biomarkers. The therapeutic areas covered include various types of cancer, with the goal of improving patient outcomes through the development of new treatments and diagnostic tools. BIOQUAL's market positioning is enhanced by its expertise in animal models and its ability to provide comprehensive research services. Future opportunities include expanding research into immunotherapy and targeted therapies. Regulatory and clinical aspects are addressed through adherence to ethical guidelines and compliance with relevant regulations. Partnerships with pharmaceutical companies and research institutions are essential for advancing cancer research.